An in vivo model of human multidrug-resistant multiple myeloma in SCID mice

William T. Bellamy, Abiodun Odeleye, Paul Finley, Beth Huizenga, William S. Dalton, Ronald S Weinstein, Evan M Hersh, Thomas M. Grogan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P-glycoprotein-expressing multidrug-resistant myeloma cells (8226/ C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multidrug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P-glycoprotein in multidrug-resistant myelomas.

Original languageEnglish (US)
Pages (from-to)691-698
Number of pages8
JournalAmerican Journal of Pathology
Volume142
Issue number3
StatePublished - Mar 1993

Fingerprint

SCID Mice
Multiple Myeloma
P-Glycoprotein
Heterografts
Doxorubicin
Urine
Pharmaceutical Preparations
Light
Abdominal Cavity
Neoplasms
Cell Line
Injections
Therapeutics
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Bellamy, W. T., Odeleye, A., Finley, P., Huizenga, B., Dalton, W. S., Weinstein, R. S., ... Grogan, T. M. (1993). An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. American Journal of Pathology, 142(3), 691-698.

An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. / Bellamy, William T.; Odeleye, Abiodun; Finley, Paul; Huizenga, Beth; Dalton, William S.; Weinstein, Ronald S; Hersh, Evan M; Grogan, Thomas M.

In: American Journal of Pathology, Vol. 142, No. 3, 03.1993, p. 691-698.

Research output: Contribution to journalArticle

Bellamy, WT, Odeleye, A, Finley, P, Huizenga, B, Dalton, WS, Weinstein, RS, Hersh, EM & Grogan, TM 1993, 'An in vivo model of human multidrug-resistant multiple myeloma in SCID mice', American Journal of Pathology, vol. 142, no. 3, pp. 691-698.
Bellamy WT, Odeleye A, Finley P, Huizenga B, Dalton WS, Weinstein RS et al. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. American Journal of Pathology. 1993 Mar;142(3):691-698.
Bellamy, William T. ; Odeleye, Abiodun ; Finley, Paul ; Huizenga, Beth ; Dalton, William S. ; Weinstein, Ronald S ; Hersh, Evan M ; Grogan, Thomas M. / An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. In: American Journal of Pathology. 1993 ; Vol. 142, No. 3. pp. 691-698.
@article{529f6f9ee1a449a3a0fcbecfcd27b3ee,
title = "An in vivo model of human multidrug-resistant multiple myeloma in SCID mice",
abstract = "We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P-glycoprotein-expressing multidrug-resistant myeloma cells (8226/ C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multidrug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P-glycoprotein in multidrug-resistant myelomas.",
author = "Bellamy, {William T.} and Abiodun Odeleye and Paul Finley and Beth Huizenga and Dalton, {William S.} and Weinstein, {Ronald S} and Hersh, {Evan M} and Grogan, {Thomas M.}",
year = "1993",
month = "3",
language = "English (US)",
volume = "142",
pages = "691--698",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - An in vivo model of human multidrug-resistant multiple myeloma in SCID mice

AU - Bellamy, William T.

AU - Odeleye, Abiodun

AU - Finley, Paul

AU - Huizenga, Beth

AU - Dalton, William S.

AU - Weinstein, Ronald S

AU - Hersh, Evan M

AU - Grogan, Thomas M.

PY - 1993/3

Y1 - 1993/3

N2 - We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P-glycoprotein-expressing multidrug-resistant myeloma cells (8226/ C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multidrug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P-glycoprotein in multidrug-resistant myelomas.

AB - We have established a reproducible in vivo model of human multiple myeloma in the severe combined immunodeficient (SCID) mouse using both the RPMI 8226 human myeloma cell line and the P-glycoprotein-expressing multidrug-resistant 8226/C1N subline. SCID mice 5 to 8 weeks of age were injected intraperitoneally with either 8226 drug-sensitive or P-glycoprotein-expressing multidrug-resistant myeloma cells (8226/ C1N). Tumors were detected within 5 days after injection by the presence of human lambda light chain excretion in the mouse urine. Growth of the tumor was observed primarily in the abdominal cavity with spread to the abdominal organs. The anti-neoplastic agent doxorubicin was effective in treating the drug-sensitive 8226 human-SCID xenografts but had no effect on the multidrug-resistant 8226/C1N human-SCID xenografts. In the 8226-sensitive xenografts, treatment with doxorubicin resulted in a sharp decline in the concentration of human lambda light chain being excreted in the mouse urine. This correlated with an increased survival of the drug-treated animals. This mouse model offers an in vivo means of evaluating efficacy and toxicity of new therapeutic approaches, including development of chemosensitizers directed against P-glycoprotein in multidrug-resistant myelomas.

UR - http://www.scopus.com/inward/record.url?scp=0027770945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027770945&partnerID=8YFLogxK

M3 - Article

VL - 142

SP - 691

EP - 698

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -